Prime Medicine (PRME) EPS (Weighted Average and Diluted) (2021 - 2025)
Historic EPS (Weighted Average and Diluted) for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$0.32.
- Prime Medicine's EPS (Weighted Average and Diluted) rose 2727.27% to -$0.32 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.44, marking a year-over-year increase of 3009.71%. This contributed to the annual value of -$1.65 for FY2024, which is 2423.79% up from last year.
- Per Prime Medicine's latest filing, its EPS (Weighted Average and Diluted) stood at -$0.32 for Q3 2025, which was up 2727.27% from -$0.41 recorded in Q2 2025.
- Prime Medicine's EPS (Weighted Average and Diluted)'s 5-year high stood at $0.72 during Q4 2022, with a 5-year trough of -$4.45 in Q4 2021.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.46 (2024), whereas its average is -$0.89.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 11617.98% in 2022, then tumbled by 20000.0% in 2023.
- Quarter analysis of 5 years shows Prime Medicine's EPS (Weighted Average and Diluted) stood at -$4.45 in 2021, then soared by 116.18% to $0.72 in 2022, then tumbled by 200.0% to -$0.72 in 2023, then skyrocketed by 50.49% to -$0.36 in 2024, then rose by 10.23% to -$0.32 in 2025.
- Its EPS (Weighted Average and Diluted) was -$0.32 in Q3 2025, compared to -$0.41 in Q2 2025 and -$0.4 in Q1 2025.